Skip to main content
HairCited

Finasteride para Alopecia Androgenética

A

Basado en 129 estudios (16 meta-analyses, 13 RCTs) con 18,623 participantes en total. 106/129 estudios muestran efectos positivos.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dfinasteride\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Conclusión

Finasteride has very strong evidence supporting its effectiveness for androgenetic alopecia and is considered a well-established first-line option backed by decades of research.

  • 106 out of 129 studies show positive effects — one of the most studied hair loss interventions
  • 16 meta-analyses and 13 RCTs provide a robust evidence base across 18,623 participants
  • Works by reducing DHT, the hormone primarily responsible for pattern hair loss
  • Topical finasteride formulations are being researched as an alternative to oral use

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Efecto: None None

Población: women with androgenetic alopecia (female pattern hair loss)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo Efecto: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs: Placebo Efecto: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo Efecto: None None
randomized controlled trial n=45 Open-label
Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of …
Dose: Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi vs: Placebo Efecto: Hair density and hair shaft diameter increased in all groups; Group C superior to Group A in Norwood p<0.01

Key Statistics

206

Estudios

24777

Participantes

Positive

A

Calificación

Referenced Papers

Aesthetic plastic surgery 2025 14 citas
Anais brasileiros de … 2025 7 citas
International journal of … 2025 5 citas
Journal of cosmetic … 2025 3 citas
European journal of … 2025 3 citas
Australian prescriber 2025 2 citas
Nature reviews. Disease … 2025
Annals of dermatology 2025
International journal of … 2024 39 citas
Indian journal of … 2024 14 citas
Dermatology (Basel, Switzerland) 2024 14 citas
Journal of cosmetic … 2024 11 citas
Journal of clinical … 2024 10 citas
Facial plastic surgery … 2024 8 citas
American family physician 2024 8 citas
Photodermatology, photoimmunology & … 2024 8 citas
International journal of … 2024 5 citas
Drugs 2023 221 citas
JAAD international 2023 80 citas
Clinical, cosmetic and … 2023 58 citas
American journal of … 2023 41 citas
Anais brasileiros de … 2023 29 citas
Journal der Deutschen … 2023 5 citas
Journal of cosmetic … 2023 3 citas
BMJ case reports 2023 2 citas
Clinics in plastic … 2023 1 citas
International journal of … 2023 1 citas
The Journal of … 2022 65 citas
Faculty reviews 2022 44 citas
Dermatologic therapy 2022 41 citas
Archivos espanoles de … 2022 9 citas
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 citas
Journal of the … 2021 42 citas
Expert opinion on … 2020 147 citas
Neurobiology of stress 2020 72 citas
Facial plastic surgery … 2020 15 citas
Dermatologic clinics 2020 15 citas
Alternative therapies in … 2020 11 citas
Journal of cosmetic … 2019 100 citas
Assay and drug … 2019 19 citas
The aging male … 2019 19 citas
Indian journal of … 2018 79 citas
Expert opinion on … 2018 38 citas
Endocrine 2017 442 citas
JAMA dermatology 2017 121 citas
Current clinical pharmacology 2017 62 citas
Actas dermo-sifiliograficas 2017 17 citas
Deutsches Arzteblatt international 2016 99 citas
The Cochrane database … 2016 18 citas
Indian journal of … 2016 8 citas
Current problems in … 2015 8 citas
Der Internist 2015
Expert opinion on … 2014 57 citas
Current opinion in … 2014 43 citas
Giornale italiano di … 2014 8 citas
Indian journal of … 2013 196 citas
Dermatologic clinics 2013 78 citas
Journal of cosmetic … 2013 62 citas
Facial plastic surgery … 2013 16 citas
International journal of … 2013
Expert opinion on … 2010 264 citas
Current opinion in … 2009 54 citas
Seminars in cutaneous … 2009 4 citas
American family physician 2009
Nihon rinsho. Japanese … 2008 6 citas
Endocrinology and metabolism … 2007 33 citas
Acta dermatovenerologica Alpina, … 2005
Revue medicale de … 2004
Praxis 2003 28 citas
American family physician 2003
Molecular and cellular … 2002
American journal of … 2000 18 citas
Southern medical journal 2000
International journal of … 1999
American family physician 1999
Journal of the … 1999
Current pharmaceutical design 1999
Journal of cutaneous … 1999
Dermatologic clinics 1998 121 citas
Annales de dermatologie … 1997

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

hairloss:
1 mg/day oral

Límite superior: 5 mg/day (BPH dose)

Dosificaciones estudiadas en la investigación

Dosificación Duración Efecto N
None -- Neutral --
None -- Neutral --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None -- Positive --
Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi -- Positive 45
None -- Positive --
various across included studies (2015-2024) -- Positive --

Mejor momento para tomar: Once daily at the same time, with or without food

Safety & Side Effects

Efectos secundarios reportados

  • Decreased libido (2-4% of users)
  • Erectile dysfunction (1-3% of users)
  • Decreased ejaculate volume
  • Breast tenderness or gynecomastia (rare)
  • Depression or mood changes (rare, debated)

Interacciones conocidas

  • No significant drug-drug interactions identified
  • May affect PSA test results (reduces PSA by ~50%)
  • Contraindicated in pregnancy (Category X teratogen)

Ingesta máxima tolerable: 5 mg/day (BPH dose)

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does Finasteride help with Alopecia Androgenética?
Based on 206 studies with 24,777 participants, there is strong evidence from multiple clinical trials that Finasteride may support Alopecia Androgenética management. Our evidence grade is A (Strong Evidence).
How much Finasteride should I take for Alopecia Androgenética?
Studies have used various dosages. A commonly studied range is 1 mg/day oral. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Finasteride?
Reported side effects may include Decreased libido (2-4% of users), Erectile dysfunction (1-3% of users), Decreased ejaculate volume, Breast tenderness or gynecomastia (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Finasteride and Alopecia Androgenética?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 206 peer-reviewed studies with 24,777 total participants. The overall direction of effect is positive.

Related Evidence

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.